# Finch Therapeutics Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/finch-therapeutics-group

- Industry: Biotechnology
- Headquarters: Somerville, US
- Website: www.finchtherapeutics.com
- Total disclosed funding: $179M
- Latest round: Series D (Sep 2, 2020)
- Investors on record: 16

## About

Finch Therapeutics Group, Inc. is a Massachusetts-based biotechnology firm focused on microbiome therapeutics, utilizing novel interventions derived from microbiota studies to address critical health challenges.Founded in 2017 and headquartered in Somerville, Massachusetts, Finch Therapeutics specializes in developing microbiome therapeutics. The company completed a successful IPO on March 18, 2021, raising USD 127.5 mn, after which it transitioned from private to public ownership. Matthew Blischak is the CEO, leading the company through pivotal developments in its product pipeline.Finch Therapeutics specializes in microbiome therapeutics, leveraging insights from human microbiota transplantation studies to create innovative microbiome assets. Their core product, CP101, targets recurrent Clostridium difficile infections, aiming to restore healthy gut flora through microbiome-based interventions. The company serves diverse clients, including healthcare providers and research institutions, in North America and Europe, where demand for advanced microbiome treatments is increasing.In 2023, Finch Therapeutics generated revenue of USD 107,000, while reporting an EBITDA of USD -82,341,000. Revenue streams are primarily derived from partnerships with healthcare institutions and pharmaceutical companies, involving licensing agreements for clinical trials and market commercialization of their microbiome assets.Following its IPO in March 2021, Finch Therapeutics plans to utilize the raised USD 127.5 mn for the advancement of its lead candidate through the final stages of clinical development. The company is focusing on launching new products, particularly expanding its microbiome therapeutics, while also targeting market expansion in Europe and North America by 2024. Finch Therapeutics aims to continue enhancing its portfolio to meet significant unmet medical needs in the healthcare sector.

## Funding rounds

- Series D, Sep 2, 2020, $90M — MSD Capital, The Baupost Group, Susquehanna Growth Equity, Willett Advisors, TouchTunes Music Corporation, Shumway Capital, OCV Partners, BDT & MSD Partners, Avenir Growth Capital, Trans-Pacific Technology Fund, SymBiosis LLC, OMX Ventures, Humboldt Fund
- Series C, May 10, 2019, $53M — 360ip, Willett Advisors, Susquehanna International Group, Morgan Noble, Shumway Capital, OCV Partners, Avenir Growth Capital, SymBiosis LLC
- Series B, Mar 1, 2018, $36M — Willett Advisors, Morgan Noble, Shumway Capital, Avenir Growth Capital

## Investors

- Willett Advisors — Series B, Series C, Series D
- Morgan Noble (https://capitalatlas.ai/funds/morgan-noble) — Series B, Series C
- Shumway Capital (https://capitalatlas.ai/funds/shumway-capital) — Series B, Series C, Series D
- Avenir Growth Capital (https://capitalatlas.ai/funds/avenir-growth-capital) — Series B, Series C, Series D
- 360ip (https://capitalatlas.ai/funds/360ip) — Series C
- Susquehanna International Group — Series C
- OCV Partners (https://capitalatlas.ai/funds/ocv-partners) — Series C, Series D
- SymBiosis LLC — Series C, Series D
- MSD Capital — Series D
- The Baupost Group — Series D
- Susquehanna Growth Equity (https://capitalatlas.ai/funds/susquehanna-growth-equity) — Series D
- TouchTunes Music Corporation — Series D
- BDT & MSD Partners (https://capitalatlas.ai/funds/bdt-msd-partners) — Series D
- Trans-Pacific Technology Fund (https://capitalatlas.ai/funds/trans-pacific-technology-fund) — Series D
- OMX Ventures (https://capitalatlas.ai/funds/omx-ventures) — Series D
- Humboldt Fund (https://capitalatlas.ai/funds/humboldt-fund) — Series D